G G Van den Eynden
Overview
Explore the profile of G G Van den Eynden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eefsen R, Vermeulen P, Christensen I, Laerum O, Mogensen M, Rolff H, et al.
Clin Exp Metastasis
. 2015 Mar;
32(4):369-81.
PMID: 25822899
Despite improved therapy of advanced colorectal cancer, the median overall survival (OS) is still low. A surgical removal has significantly improved survival, if lesions are entirely removed. The purpose of...
2.
Pastushenko I, Vermeulen P, Van den Eynden G, Rutten A, Carapeto F, Dirix L, et al.
Br J Dermatol
. 2014 Mar;
171(2):220-33.
PMID: 24641095
Malignant melanoma represents < 10% of all skin cancers but is responsible for the majority of skin-cancer-related deaths. Metastatic melanoma has historically been considered as one of the most therapeutically...
3.
Peeters D, De Laere B, Van den Eynden G, Van Laere S, Rothe F, Ignatiadis M, et al.
Br J Cancer
. 2013 Mar;
108(6):1358-67.
PMID: 23470469
Background: Molecular characterisation of single circulating tumour cells (CTCs) holds considerable promise for predictive biomarker assessment and to explore CTC heterogeneity. We evaluate a new method, the DEPArray system, that...
4.
Vanlander A, Jorens P, Smet J, De Paepe B, Verbrugghe W, Van den Eynden G, et al.
Acta Anaesthesiol Scand
. 2012 Jan;
56(4):520-5.
PMID: 22260353
Propofol is an anesthetic agent widely used for induction and maintenance of anesthesia, and sedation in children. Although generally considered as reliable and safe, administration of propofol can occasionally induce...
5.
Trinh X, van Dam P, Vermeulen P, Van Laere S, Van den Eynden G, Tjalma W, et al.
Clin Transl Oncol
. 2011 Nov;
13(11):805-8.
PMID: 22082645
BACKGROUND The mechanisms of tumour progression during anti-VEGF-A treatment are poorly understood. PATIENTS AND MATERIALS Two patients with metastatic breast cancer are described who developed new metastases while receiving anti-VEGF-A...
6.
Peeters D, Van den Eynden G, van Dam P, Prove A, Benoy I, van Dam P, et al.
Br J Cancer
. 2011 Apr;
104(9):1472-7.
PMID: 21468046
Background: The enumeration of circulating tumour cells (CTC) has prognostic significance in patients with metastatic breast cancer (MBC) and monitoring of CTC levels over time has considerable potential to guide...
7.
van Dongen J, Michielsen P, Van den Eynden G, Pelckmans P, Francque S
Acta Gastroenterol Belg
. 2010 May;
73(1):46-51.
PMID: 20458850
Because of the rising incidence of obesity the use of bariatric surgery is also increasing. For the obese it is the only treatment with a proven long-term benefit on weight,...
8.
Van der Auwera I, Van Laere S, van den Bosch S, Van den Eynden G, Trinh B, van Dam P, et al.
Br J Cancer
. 2008 Oct;
99(10):1735-42.
PMID: 18841156
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter occurs in about 40% of breast tumours and has been correlated with reduced APC protein levels. To what extent epigenetic...
9.
Van Laere S, Van der Auwera I, Van den Eynden G, van Dam P, van Marck E, Vermeulen P, et al.
Br J Cancer
. 2007 Aug;
97(5):659-69.
PMID: 17700572
Activation of NF-kappaB in inflammatory breast cancer (IBC) is associated with loss of estrogen receptor (ER) expression, indicating a potential crosstalk between NF-kappaB and ER. In this study, we examined...
10.
Van den Eynden G, Van der Auwera I, Van Laere S, Trinh X, Colpaert C, van Dam P, et al.
J Pathol
. 2007 Aug;
213(1):56-64.
PMID: 17674348
Angiogenesis and lymphangiogenesis are complex processes, driven by multiple factors. In primary breast tumours (PTs), VEGFA, -C and -D are the most important (lymph)angiogenic factors. The induction of lymphangiogenesis in...